Order Article Reprints

Fianchi L, Bonanni M, Borchiellini A, Valeri F, Giuffrida G, Grasso S, Fozza C, Ponta M, Tiscia GL, Grandone E, et al. Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study. Journal of Clinical Medicine. 2024; 13(21):6561. https://doi.org/10.3390/jcm13216561

Fianchi, Luana, Matteo Bonanni, Alessandra Borchiellini, Federica Valeri, Gaetano Giuffrida, Stephanie Grasso, Claudio Fozza, Michele Ponta, Giovanni L. Tiscia, Elvira Grandone, and et al. 2024. "Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study" Journal of Clinical Medicine 13, no. 21: 6561. https://doi.org/10.3390/jcm13216561

Fianchi, L., Bonanni, M., Borchiellini, A., Valeri, F., Giuffrida, G., Grasso, S., Fozza, C., Ponta, M., Tiscia, G. L., Grandone, E., Vianelli, N., Dedola, A., Pirozzi, T., Sacco, M., Lancellotti, S., & De Cristofaro, R. (2024). Real-World Data on Effectiveness and Safety of First-Line Use of Caplacizumab in Italian Centers for the Treatment of Thrombotic Thrombocytopenic Purpura: The Roscapli Study. Journal of Clinical Medicine, 13(21), 6561. https://doi.org/10.3390/jcm13216561